A Phase 1b Pharmacodynamic Study of VK0214 in Adrenomyeloneuropathy.

• Research type

  Research Study

• Full title

  Phase 1b, Multi-center, Randomized, Double-Blind, Placebo-Controlled, Rising Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of VK0214, in Subjects with the Adrenomyeloneuropathy Form (AMN) of X-linked Adrenoleukodystrophy (X-ALD).

• IRAS ID

  1005780

• Contact name

  Marianne Mancini

• Contact email

  mmancini@vikingtherapeutics.com

• Sponsor organisation

  Viking Therapeutics Inc.

• Eudract number

  2022-000791-19

• Clinicaltrials.gov Identifier

  NCT04973657

• Research summary

  A Phase 1b Pharmacodynamic Study of VK0214 in Adrenomyeloneuropathy.

• REC name

  HSC REC A

• REC reference

  22/NI/0128

• Date of REC Opinion

  18 Nov 2022

• REC opinion

  Further Information Favourable Opinion